Targets of immunotherapy for hepatocellular carcinoma: An update

Table 6 Ongoing clinical trials on vaccine therapy for hepatocellular carcinoma

Clinical trial #	Phase	Agent/vaccine	Design/aim	Status
NCT01974661	Phase I	COMBIG-DC (ilixadencel)	Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects	Completed; No results posted
NCT01821482	Phase II	DC-CIK	To evaluate the efficacy of DC-CIK for HCC	Unknown/not yet recruiting
NCT02638857	Phase I/II	DC precision multiple antigen T cell	To evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with TACE in HCC	Unknown/was recruiting
NCT02882659	Phase I	Autologous dendritic killer cell	To evaluate the safety in patients with metastatic solid tumor; To evaluate the maximum tolerated dose	Unknown/was active, not recruiting
NCT03674073	Phase I	Personalized neoantigen-based dendritic cell	A single institution, open-label, multi-arm, pilot study; DC vaccine combined with microwave ablation in HCC	Unknown/was recruiting
NCT03203005	Phase I/II	Cancer vaccine called IMA970A combined with CV8102	To investigate the safety; To check if this combination can trigger an immune response against the tumor in HCC	Completed; No results posted
NCT02562755	Phase III	Pexastimogene devacirepvec (Pexa Vec) and sorafenib	To investigate if the combined treatment increases survival compared to treatment with sorafenib alone in HCC	Completed

DCs: Dendritic cells; CIK: Cytokine-induced killer; HCC: Hepatocellular carcinoma.